title: In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.
abstract: OBJECTIVE
  The goal of the present study was to test the (177)Lu-labelled anti-PSMA monoclonal antibody 3/F11 ((177)Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model.
  
  
  METHODS
  The mAb 3/F11 was (177)Lu labelled using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelating agent. DOTA-3/F11 was tested for cell binding and serum immunoreactivity by flow cytometry. The biodistribution and the therapeutic efficacy of (177)Lu-DOTA-3/F11 in mice bearing PSMA-positive C4-2 prostate cancer xenografts were evaluated.
  
  
  RESULTS
  3/F11 and DOTA-3/F11 showed high and specific cell binding and similar serum half-lives of approximately seven days. Biodistribution studies revealed an increasing tumour uptake of (177)Lu DOTA-3/F11 over time with maximum tumour-to-muscle and tumour-to-blood ratios after 72 h. A single dose of 1 MBq (177)Lu-DOTA-3/F11 inhibited tumour growth and prolonged survival.
  
  
  CONCLUSIONS
  This study indicated that (177)Lu-DOTA-3/F11 may be a suitable radioimmunotherapeutic agent for the treatment of prostate cancer.
authors.affiliation: Department of Nuclear Medicine, University Hospital Freiburg, 79106 Freiburg, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Behe
authors.forename: Karen
authors.initials: K
authors.lastname: Alt
authors.forename: Friederike
authors.initials: F
authors.lastname: Deininger
authors.forename: Patrick
authors.initials: P
authors.lastname: Bühler
authors.forename: Ulrich
authors.initials: U
authors.lastname: Wetterauer
authors.forename: Wolfgang A
authors.initials: WA
authors.lastname: Weber
authors.forename: Ursula
authors.initials: U
authors.lastname: Elsässer-Beile
authors.forename: Philipp
authors.initials: P
authors.lastname: Wolf
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000954:Antigens, Surface / Q000276:immunology*; D045744:Cell Line, Tumor; D056831:Coordination Complexes / Q000627:therapeutic use*; D043425:Glutamate Carboxypeptidase II / Q000276:immunology*; D006801:Humans; D007553:Isotope Labeling; D008187:Lutetium / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D011868:Radioisotopes; D023041:Xenograft Model Antitumor Assays
chemical_list: C558120:177Lu-DOTA-3-F11; D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D056831:Coordination Complexes; D011868:Radioisotopes; D008187:Lutetium; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II